Evidence map›Paper›PMID 35817776›Full record

ArticleSignal transduction and targeted therapy2022

STING cg16983159 methylation: a key factor for glioblastoma immunosuppression.

Lei Qiu, Yang Meng, Junhong Han

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Chromosomal Instability Drives Glioblastoma Heterogeneity and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Harnessing innate immune pathways for therapeutic advancement in cancer.Signal transduction and targeted therapy · 2024
    Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Lei Qiu *Research Laboratory of Tumor Epigenetics and Genomics, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, 610041, Chengdu, P.R. China.
Yang Meng *Research Laboratory of Tumor Epigenetics and Genomics, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, 610041, Chengdu, P.R. China.
Junhong HanResearch Laboratory of Tumor Epigenetics and Genomics, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, 610041, Chengdu, P.R. China. hjunhong@scu.edu.cn.ORCID 0000-0002-3371-8698

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsGlioblastomaDNA MethylationHumansImmunosuppression Therapy

Identifiers

PMID35817776
PMCPMC9273597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.